Clinical Application of Pharmacogenetics: Where are We Now?
Pharmacogenetic (PGx) testing has the potential to improve drug therapy in an individual by informing appropriate drug dosing or drug selection in order to maximize efficacy and safety. Although multiple studies have illustrated the potential benefits of such testing when applied to specific drugs across a broad range of therapy areas, the uptake of PGx testing in routine clinical practice has been relatively limited. Implementation appears to be hampered by the absence of sufficiently strong evidence linking the results of testing with actionable benefits in terms of clinical outcomes. Meanwhile, there are now adequate data to allow dosing recommendations as have been developed by bodies including the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) in several settings, including TPMT/thiopurines, CYP2C19/clopidogrel, CYP2D6/codeine, VKORC1-CYP2C9/warfarin, HLA-B*5701/abacavir, SLCO1B1/simvastatin and HLAB*5801/allopurinol. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) have also recently initiated surveys in order to better understand the extent of, and the role played by, PGx testing in clinical practice. This should help identify where further training and education may be beneficial. To this end, in collaboration with ESPT, the IFCC Pharmacogenetic Laboratory Network has now been formed, with the aim of improving the uptake and quality of PGx testing.
Dept. Clinical Chemistry, Erasmus MC Rotterdam, The Netherlands ; Chair IFCC Task Force on Pharmacogenetics.
Ron Hn
RH
van Schaik
guidelines; pharmacogenetic testing; survey
N Engl J Med. 2013 Dec 12;369(24):2283-93
24251361
Dialogues Clin Neurosci. 2010;12(1):69-76
20373668
Mol Diagn Ther. 2012 Dec;16(6):331-45
23192462
Pharmacol Rev. 2013 May 17;65(3):987-1009
23686351
J Natl Cancer Inst. 2012 Mar 21;104(6):441-51
22395644
Heart. 2012 Jan;98 (2):100-8
21693476
N Engl J Med. 2011 Feb 3;364(5):481; author reply 482
21288102
Clin Pharmacol Ther. 2013 Aug;94(2):185-7
23872831
Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1065-77
19572825
Pharmacogenomics. 2013 Jul;14(9):1099-118
23837483
Clin Pharmacol Ther. 2010 Jun;87(6):721-6
20393454
JAMA. 2009 Oct 7;302(13):1429-36
19809024
Clin Pharmacol Ther. 2011 May;89(5):708-17
21451508
N Engl J Med. 2008 Feb 7;358(6):568-79
18256392
JAMA. 2011 Dec 28;306(24):2704-14
22203539
N Engl J Med. 2013 Dec 12;369(24):2294-303
24251363
Clin Pharmacol Ther. 2014 Feb;95(2):216-27
24060820
J Clin Oncol. 2013 Jul 20;31(21):2753-5
23775974
N Engl J Med. 2013 Dec 12;369(24):2304-12
24251360
N Engl J Med. 2003 Feb 6;348(6):538-49
12571262
Clin Pharmacol Ther. 2013 Aug;94(2):183-5
23872830
Clin Pharmacol Ther. 2013 Aug;94(2):169-72
23872826